vs
Side-by-side financial comparison of Hologic (HOLX) and Reynolds Consumer Products Inc. (REYN). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $1.0B, roughly 1.0× Reynolds Consumer Products Inc.). Hologic runs the higher net margin — 17.1% vs 11.4%, a 5.7% gap on every dollar of revenue. On growth, Hologic posted the faster year-over-year revenue change (2.5% vs 1.2%). Hologic produced more free cash flow last quarter ($215.2M vs $200.0M). Over the past eight quarters, Reynolds Consumer Products Inc.'s revenue compounded faster (11.4% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
The Rival Company is an American manufacturer of small appliances that produces products under the Bionaire, Crock-Pot, Fasco, Patton, Pollenex, Rival, Simer, and White Mountain brands. It became a wholly owned subsidiary of Holmes Products Corp. in 1999, and later became a brand of Sunbeam Products, a subsidiary of Jarden Corporation, which purchased Holmes in 2005. Jarden, in turn, merged with Newell Rubbermaid in 2016. It is now part of the Newell Brands company.
HOLX vs REYN — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $1.0B |
| Net Profit | $179.1M | $118.0M |
| Gross Margin | 56.0% | 25.7% |
| Operating Margin | 22.6% | 14.8% |
| Net Margin | 17.1% | 11.4% |
| Revenue YoY | 2.5% | 1.2% |
| Net Profit YoY | -10.9% | -1.7% |
| EPS (diluted) | $0.79 | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $1.0B | ||
| Q3 25 | $1.0B | $931.0M | ||
| Q2 25 | $1.0B | $938.0M | ||
| Q1 25 | $1.0B | $818.0M | ||
| Q4 24 | $1.0B | $1.0B | ||
| Q3 24 | $988.0M | $910.0M | ||
| Q2 24 | $1.0B | $930.0M | ||
| Q1 24 | $1.0B | $833.0M |
| Q4 25 | $179.1M | $118.0M | ||
| Q3 25 | $187.2M | $79.0M | ||
| Q2 25 | $194.9M | $73.0M | ||
| Q1 25 | $-17.4M | $31.0M | ||
| Q4 24 | $201.0M | $120.0M | ||
| Q3 24 | $178.6M | $86.0M | ||
| Q2 24 | $194.5M | $97.0M | ||
| Q1 24 | $169.9M | $49.0M |
| Q4 25 | 56.0% | 25.7% | ||
| Q3 25 | 55.6% | 25.0% | ||
| Q2 25 | 56.3% | 24.1% | ||
| Q1 25 | 37.5% | 23.1% | ||
| Q4 24 | 56.8% | 27.6% | ||
| Q3 24 | 56.4% | 26.3% | ||
| Q2 24 | 55.4% | 27.5% | ||
| Q1 24 | 53.3% | 24.1% |
| Q4 25 | 22.6% | 14.8% | ||
| Q3 25 | 22.6% | 11.0% | ||
| Q2 25 | 24.9% | 10.2% | ||
| Q1 25 | -0.7% | 5.1% | ||
| Q4 24 | 22.5% | 15.5% | ||
| Q3 24 | 23.3% | 12.4% | ||
| Q2 24 | 24.1% | 12.4% | ||
| Q1 24 | 20.7% | 7.8% |
| Q4 25 | 17.1% | 11.4% | ||
| Q3 25 | 17.8% | 8.5% | ||
| Q2 25 | 19.0% | 7.8% | ||
| Q1 25 | -1.7% | 3.8% | ||
| Q4 24 | 19.7% | 11.7% | ||
| Q3 24 | 18.1% | 9.5% | ||
| Q2 24 | 19.2% | 10.4% | ||
| Q1 24 | 16.7% | 5.9% |
| Q4 25 | $0.79 | $0.55 | ||
| Q3 25 | $0.84 | $0.38 | ||
| Q2 25 | $0.86 | $0.35 | ||
| Q1 25 | $-0.08 | $0.15 | ||
| Q4 24 | $0.87 | $0.57 | ||
| Q3 24 | $0.75 | $0.41 | ||
| Q2 24 | $0.82 | $0.46 | ||
| Q1 24 | $0.72 | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $147.0M |
| Total DebtLower is stronger | $2.5B | $1.6B |
| Stockholders' EquityBook value | $5.2B | $2.3B |
| Total Assets | $9.2B | $4.9B |
| Debt / EquityLower = less leverage | 0.48× | 0.70× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | $147.0M | ||
| Q3 25 | $2.2B | $53.0M | ||
| Q2 25 | $1.9B | $57.0M | ||
| Q1 25 | $1.6B | $58.0M | ||
| Q4 24 | $2.0B | $137.0M | ||
| Q3 24 | $2.3B | $96.0M | ||
| Q2 24 | $2.4B | $101.0M | ||
| Q1 24 | $2.2B | $135.0M |
| Q4 25 | $2.5B | $1.6B | ||
| Q3 25 | $2.5B | $1.6B | ||
| Q2 25 | $2.5B | $1.6B | ||
| Q1 25 | $2.5B | $1.6B | ||
| Q4 24 | $2.5B | $1.7B | ||
| Q3 24 | $2.5B | $1.7B | ||
| Q2 24 | $2.5B | $1.8B | ||
| Q1 24 | $2.6B | $1.8B |
| Q4 25 | $5.2B | $2.3B | ||
| Q3 25 | $5.0B | $2.2B | ||
| Q2 25 | $4.8B | $2.1B | ||
| Q1 25 | $4.6B | $2.1B | ||
| Q4 24 | $4.8B | $2.1B | ||
| Q3 24 | $5.1B | $2.1B | ||
| Q2 24 | $5.0B | $2.0B | ||
| Q1 24 | $4.8B | $2.0B |
| Q4 25 | $9.2B | $4.9B | ||
| Q3 25 | $9.0B | $4.9B | ||
| Q2 25 | $8.8B | $4.9B | ||
| Q1 25 | $8.5B | $4.8B | ||
| Q4 24 | $8.7B | $4.9B | ||
| Q3 24 | $9.2B | $4.8B | ||
| Q2 24 | $8.9B | $4.9B | ||
| Q1 24 | $8.7B | $4.9B |
| Q4 25 | 0.48× | 0.70× | ||
| Q3 25 | 0.50× | 0.75× | ||
| Q2 25 | 0.52× | 0.76× | ||
| Q1 25 | 0.55× | 0.77× | ||
| Q4 24 | 0.53× | 0.79× | ||
| Q3 24 | 0.49× | 0.84× | ||
| Q2 24 | 0.51× | 0.87× | ||
| Q1 24 | 0.53× | 0.92× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $237.0M |
| Free Cash FlowOCF − Capex | $215.2M | $200.0M |
| FCF MarginFCF / Revenue | 20.5% | 19.3% |
| Capex IntensityCapex / Revenue | 1.4% | 3.6% |
| Cash ConversionOCF / Net Profit | 1.28× | 2.01× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $316.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | $237.0M | ||
| Q3 25 | $355.1M | $93.0M | ||
| Q2 25 | $343.3M | $91.0M | ||
| Q1 25 | $169.4M | $56.0M | ||
| Q4 24 | $189.3M | $182.0M | ||
| Q3 24 | $367.0M | $124.0M | ||
| Q2 24 | $405.8M | $84.0M | ||
| Q1 24 | $292.4M | $99.0M |
| Q4 25 | $215.2M | $200.0M | ||
| Q3 25 | $341.4M | $48.0M | ||
| Q2 25 | $330.5M | $51.0M | ||
| Q1 25 | $153.9M | $17.0M | ||
| Q4 24 | $172.5M | $141.0M | ||
| Q3 24 | $350.6M | $93.0M | ||
| Q2 24 | $385.3M | $65.0M | ||
| Q1 24 | $279.6M | $70.0M |
| Q4 25 | 20.5% | 19.3% | ||
| Q3 25 | 32.5% | 5.2% | ||
| Q2 25 | 32.3% | 5.4% | ||
| Q1 25 | 15.3% | 2.1% | ||
| Q4 24 | 16.9% | 13.8% | ||
| Q3 24 | 35.5% | 10.2% | ||
| Q2 24 | 38.1% | 7.0% | ||
| Q1 24 | 27.5% | 8.4% |
| Q4 25 | 1.4% | 3.6% | ||
| Q3 25 | 1.3% | 4.8% | ||
| Q2 25 | 1.3% | 4.3% | ||
| Q1 25 | 1.5% | 4.8% | ||
| Q4 24 | 1.6% | 4.0% | ||
| Q3 24 | 1.7% | 3.4% | ||
| Q2 24 | 2.0% | 2.0% | ||
| Q1 24 | 1.3% | 3.5% |
| Q4 25 | 1.28× | 2.01× | ||
| Q3 25 | 1.90× | 1.18× | ||
| Q2 25 | 1.76× | 1.25× | ||
| Q1 25 | — | 1.81× | ||
| Q4 24 | 0.94× | 1.52× | ||
| Q3 24 | 2.05× | 1.44× | ||
| Q2 24 | 2.09× | 0.87× | ||
| Q1 24 | 1.72× | 2.02× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
REYN
| Reynolds Cooking And Baking | $397.0M | 38% |
| Hefty Waste And Storage | $247.0M | 24% |
| Tableware Products | $229.0M | 22% |
| Presto Products | $164.0M | 16% |
